Big Pharma Must Diversify To Tackle Antimicrobial Resistance
Biotechs Lead On R&D But Need Resources
Big pharma must bet on biotech if the industry is to tackle the looming issue of superbugs, argues the Access To Medicine Foundation.
Big pharma must bet on biotech if the industry is to tackle the looming issue of superbugs, argues the Access To Medicine Foundation.